InvestmentPitch Media Video Discusses Voyageur Pharmaceuticals’ Notice of Work with the BC Ministry of Mines, for the Removal of 2,000 Tonnes of Barium Sulfate from its Frances Creek Project

Rhea-AI Summary

Voyageur Pharmaceuticals (VYYRF) has submitted a notice of work to the BC Ministry of Mines for removing 2,000 tonnes of barium sulfate from its Frances Creek Project. This project is crucial as it is designed to support the pharmaceutical barite market. Upon approval, the company will excavate two zones to extract high-purity barium sulfate, essential for barium contrast manufacturing. A Preliminary Economic Assessment indicated a strong NPV of $344 million and an IRR of 137%. The company plans to build a pilot plant to enhance production capabilities, aiming for full-scale operations by 2024.

Positive

• Submitted a notice of work for barium sulfate removal, critical for pharmaceutical applications.
• Strong economic metrics with a NPV of $344 million and an IRR of 137%.
• Plans to construct a lower-cost barium API pilot plant to enhance production efficiency.
• Aiming for full production by 2024, increasing potential market share in the pharmaceutical sector.

Negative

• None.

VANCOUVER, British Columbia, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Voyageur Pharmaceuticals (TSXV:VM) (OTCPink:VYYRF) has submitted a notice of work with the BC Ministry of Mines, for the removal of 2,000 tonnes of barium sulfate from its Frances Creek Project. The Frances Creek project is one of the company’s three 100% owned projects in British Columbia with grade suitable for the pharmaceutical barite marketplace.

A Media Snippet accompanying this announcement is available by clicking on the image or link below:

For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company. The video is available for viewing on “InvestmentPitch.com” and on “YouTube”. If these links are not enabled, please visit www.InvestmentPitch.com and enter “Voyageur” in the search box.

Upon approval from the BC Ministry of Mines, Voyageur will excavate small, 2-metre-wide surface trenches, to remove 1,000 tonnes of barite from the A zone and 1,000 tonnes from the B zone. This tonnage is expected to allow for complete testing and modifications to the new barium active pharmaceutical ingredient or API pilot plant, that the company plans to construct, with construction tentatively scheduled to begin in 2023.

Upon completion of this work program, a notice of work for a Small Quarry will be submitted to the BC Ministry of Mines, with plans for full production in 2024.

With the 2,000 tonnes expected to be a high-grade sample with low waste, Voyageur anticipates extracting 1,000 to 1,200 tonnes of high purity barium sulfate from this sample, to be used in barium contrast manufacturing.

To put the number in perspective, 1,000 tonnes of pharmaceutical grade barium sulfate, can create:

• Approximately 111,111,000 bottles of SmoothX smoothie contrast media, or
   
• Approximately 3,000,000 bottles of HDX powdered contrast media

Contrast materials, which may be taken orally or rectally, are used to improve pictures of the inside of the body helping to distinguish or "contrast" selected areas of the body from surrounding tissue allowing the radiologist to distinguish normal from abnormal conditions.

SGS Canada completed a Preliminary Economic Assessment and assigned a NPV of $344 million with an IRR of 137%, to the Frances Creek project.

The company is designing a new barium API pilot plant, with the goal of reducing the capital required, from the $36 million over three years, stated in the PEA. Voyageur’s plan is to build a lower cost production facility, fast track production, process the 2,000 tonnes of barium sulfate and complete full feasibility based on live real time sales of product. This is expected to allow the Frances Creek project to be valued with a NI 43-101 defined reserve.

Voyageur is moving forward with its business plan of becoming the only fully integrated company in the radiology medical field, by controlling all primary input costs under the motto of: "From the Earth to the Bottle".

The shares are currently trading at $0.105. For more information, please visit www.VoyageurPharmaceuticals.ca, contact Brent Willis, President and CEO, by email at brent@vpharma.ca, or Al Deslauriers, CFO, at albertl@vpharma.ca.

Disclaimer

The information in this InvestmentPitch Media Ltd video is for the viewers information only. Voyageur Pharma has paid a fee not exceeding $2,000 in cash to have its current news release produced in video format. The corporate information is based on information that is publicly available. Any information provided by InvestmentPitch Media Ltd., through its media services is not to be construed as a recommendation or suggestion or offer to buy or sell securities but is provided solely as an informational media service. InvestmentPitch Media Ltd makes no warranties or undertakings as to the accuracy or completeness of this information. All due diligence should be done by the viewer or their financial advisor. Investing in securities is speculative and carries risk.

About InvestmentPitch Media

InvestmentPitch Media leverages the power of video, which together with its extensive distribution, positions a company’s story ahead of the 1,000's of companies seeking awareness and funding from the financial community. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.

CONTACT:
InvestmentPitch Media
Barry Morgan, CFO
bmorgan@investmentpitch.com

FAQ

What is the purpose of Voyageur Pharmaceuticals' recent notice of work submission?

The notice aims to remove 2,000 tonnes of barium sulfate from the Frances Creek Project for pharmaceutical applications.

What are the economic projections for Voyageur Pharmaceuticals' Frances Creek Project?

The Preliminary Economic Assessment indicates a net present value (NPV) of $344 million and an internal rate of return (IRR) of 137%.

When does Voyageur Pharmaceuticals plan to begin construction of its pilot plant?

Construction of the new barium API pilot plant is tentatively scheduled to begin in 2023.

What high-purity product does Voyageur Pharmaceuticals intend to produce from the extracted barium sulfate?

Voyageur aims to produce barium sulfate for use in barium contrast manufacturing.

What is the expected timeline for full production at the Frances Creek Project?

Full production is planned for 2024 following the completion of the initial work program.